On the deal, Clifford Chance and Mourant advised CBC Group and Mubadala; Cleary Gottlieb acted as onshore legal advisors to Mubadala. CBC Group, Asia’s largest healthcare-dedicated...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Keymed Biosciences (Chengdu) Co., Ltd. on the deal. Keymed Biosciences (Chengdu) Co., Ltd. completed an out-licensing transaction with Belenos Biosciences, Inc.to exclusively...
You must be a Standard 1 Year member to access this content.
Clifford Chance acted for Ipsen Pharma GmbH. Ipsen Pharma GmbH has filed a constitutional complaint against the provisions of the latest “austerity laws”, i.e., the Act on...
You must be a Standard 1 Year member to access this content.
Clifford Chance advised Paragon Partners on the investment. Paragon invests in the Primed Group, a leading provider of medical consumables and sterilization services based in Halberstadt,...
You must be a Standard 1 Year member to access this content.
Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised Neuraxpharm Group on the deal. Neuraxpharm Group acquired two portfolios of established products from Sanofi which are marketed globally in more than...
You must be a Standard 1 Year member to access this content.
Clifford Chance has advised funds managed by DWS on the deal, while Latham & Watkins has advised Summit Partners on the sale. DWS acquired and integrated Radioonkologienetzwerk...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised AXA Investment Managers on the deal. Clifford Chance LLP advised the consortium and Sullivan & Cromwell LLP advised GS Infrastructure. Latham...
You must be a Standard 1 Year member to access this content.
